Medical technology manufacturing company Boston Scientific has acquired Obsidio, a company that makes technology used in the embolization of blood vessels in the peripheral vasculature.
Embolization is a procedure to reduce blood flow to a tumor and prevent hemorrhaging. Obsidio's Gel Embolic Material product line is designed to minimize embolization procedure preparation time by delivering the Gel Embolic Material through a catheter, according to the Aug. 15 Boston Scientific news release.
"The Gel Embolic Material technology combines benefits of currently available embolics, such as precise control of a solid and malleability of a liquid, to create a unique technology that offers procedural efficiency and a more personalized therapy for patients," said Peter Pattison, president, interventional oncology and embolization, peripheral interventions at Boston Scientific. "This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions."